Quarterly ResultApr 28, 2026, 07:30 AM
KNSA Q1 Revenue $214.3M, +56% YoY; ARCALYST Guidance Raised to $930-945M
AI Summary
Kiniksa Pharmaceuticals reported strong first quarter 2026 financial results, with ARCALYST net product revenue reaching $214.3 million, a 56% year-over-year increase. The company raised its 2026 ARCALYST net product revenue guidance to $930-$945 million, reflecting continued strong adoption. Kiniksa also provided positive updates on its clinical pipeline, expecting KPL-387 Phase 2 data in 2H 2026 and initiation of its Phase 3 trial by year-end, alongside a Phase 1 trial for KPL-1161.
Key Highlights
- ARCALYST Q1 2026 net product revenue was $214.3 million, representing 56% year-over-year growth.
- Raised 2026 ARCALYST net product revenue guidance to $930-$945 million from $900-$920 million.
- Total revenue for Q1 2026 was $214.3 million, compared to $137.8 million for Q1 2025.
- Net income for Q1 2026 was $22.6 million, compared to $8.5 million for Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $468.1 million as of March 31, 2026.
- KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026.
- KPL-387 Phase 3 pivotal trial expected to initiate by year-end 2026.
- KPL-1161 Phase 1 first-in-human clinical trial expected by year-end 2026.